Castle Biosciences Inc (NAS:CSTL)
$ 23.58 -0.9 (-3.68%) Market Cap: 650.98 Mil Enterprise Value: 454.21 Mil PE Ratio: 0 PB Ratio: 1.62 GF Score: 79/100

Castle Biosciences Inc at Canaccord Genuity Growth Conference Transcript

Aug 10, 2022 / 05:00PM GMT
Release Date Price: $34.32 (+12.01%)
Kyle Alexander Mikson
Canaccord Genuity Corp., Research Division - Analyst

Hi, everyone. Welcome to the Canaccord Genuity 42nd Annual Global Growth Conference. I'm Kyle Mikson. I cover Life Science Tools and Diagnostics at Canaccord, and I'm pleased to present to you the management team from Castle Biosciences here with us today. We have Derek Maetzold, CEO; and then Frank Stokes, CFO. Thanks, Derek, Frank, for joining us today.

Derek J. Maetzold
Castle Biosciences, Inc. - Founder, CEO, President & Director

Thank you, Kyle.

Kyle Alexander Mikson
Canaccord Genuity Corp., Research Division - Analyst

And just as background, Castle provides a leading class of dermatologic cancer tests as well as now GI cancer tests, prognostic tests as well as mental health tests, too. So we're going to cover all that today. Looking forward to it.

Questions & Answers

Kyle Alexander Mikson
Canaccord Genuity Corp., Research Division - Analyst

So maybe just on the second

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot